Participating Companies


Abide Tx
Serine hy­dro­lase-tar­get­ed ther­a­peu­tics har­ness­ing the en­do­cann­abi­noid sys­tem to ad­dress neu­ro­log­i­cal and pain di­s­or­ders w. limit­ed or no treat­ment op­tions. Ph 2: Tourette Syn­drome on­go­ing with da­ta ex­pect­ed in 1Q20; Ph 1b: neu­ro­path­ic pain com­plete, with plans to ini­ti­ate Ph 2 in 1H19. [more in­for­ma­tion]
Affimed N.V. [AFMD] US$170 MM MCap
NK cell en­gager AFM13 (CD30/CD16A) that is poised to en­ter a Phase 2 reg­is­tra­tion study in CD30-pos­i­tive pe­ripher­al T cell lym­pho­ma and an in­vesti­ga­tor-spon­sored study by MDACC of AFM13 com­bined with al­lo­gene­ic NK cells in re­lapsed/re­frac­to­ry CD30-pos­i­tive lym­pho­ma. Af­fimed al­so plans to file an IND in the third quar­ter of 2019 for AFM24, the com­pany’s in­nate cell en­gager that tar­gets EGFR-ex­press­ing solid tu­mors. [more in­for­ma­tion]
Anavex Life Sciences Corp. [AVXL] US$132 MM MCap
The anal­y­sis of RNA and whole ex­ome DNA genome se­quenc­ing da­ta has char­ac­ter­ized sev­er­al ge­nom­ic al­ter­a­tions in well-char­ac­ter­ized tar­gets that can be used as bio­mark­ers to iden­ti­fy op­ti­mal pa­tients in forth­com­ing clin­i­cal trials (Rett, Alzheimer’s, and Parkin­son’s). [more in­for­ma­tion]
Catalyst Pharmaceuticals, Inc. [CPRX] US$593 MM MCap
Fir­dapse ap­proved 11/18, Q1 sales of $12m: 380 ac­tive LEMS pa­tients on ther­a­py (a/o May 9) [more in­for­ma­tion]
Flex Pharma, Inc. [FLKS]
Pos­i­tive da­ta in Ph2 ex­plo­ra­to­ry study in MS pa­tients - sta­tis­ti­cal­ly sig­ni­f­i­cant 27.3% re­duc­tion in the fre­quen­cy of cramps/spasms com­pared with con­trol. Ph 2 trials on­go­ing in ALS and Char­cot-Marie-Tooth with da­ta ex­pect­ed in ear­ly 2019. MoA is based up­on nov­el in­sights in neu­ro­mus­cu­lar phy­si­ol­o­gy (ion and TRP bi­ol­o­gy) from No­bel Prize win­n­ers. [more in­for­ma­tion]
NeuroRx
The Com­pany re­port­ed Phase 2 ef­fi­ca­cy and safe­ty da­ta for NRX-011 in De­cem­ber 2018, suggest­ing po­ten­tial for NRX-101 in main­tain­ing re­mis­sion from sev­er­al bipo­lar de­pres­sion with acute sui­ci­dal idea­tion fol­low­ing an ini­tial sta­bi­l­iza­tion with ke­tamine. [more in­for­ma­tion]
Oryzon Genomics [ORY:MA]
Tar­get­ing ly­sine spe­cif­ic demethy­lase 1 (LS­D1, aka KD­M1A). Lead CNS com­pound in 3 Phase 2a trials in MS, AD and bas­ket trial. Onc com­pound in 2 com­bo Phase 2a trials in AML and SCLC. Da­ta exp mid-2019 [more in­for­ma­tion]
PAION AG [PAIOF] US$153 MM MCap
Remi­ma­zo­lam: short-act­ing anes­thet­ic. Ph 3 study in pro­ce­du­ral se­da­tion in US. Safe­ty da­ta in ASA III/IV pa­tients in Ph 3 colonos­copy study and Ph 3 bron­chos­copy study. US ap­pro­val filed by part­n­er Cos­mo Phar­ma­ceu­ti­cals in June 2019. Ini­ti­at­ed Ph 3 in gen­er­al anes­th­e­sia in EU in Ju­ly 2018, exp com­ple­tion 2019. [more in­for­ma­tion]
Savara Inc. [SVRA] US$91 MM MCap
Or­phan lung dis­ease; Mol­gradex, Ph 3, in­haled GM-CSF: au­toim­mune pul­mo­nary alve­o­lar pro­tei­no­sis (aPAP), Ph 2a: non­tu­ber­cu­lous my­cobac­te­ria (NTM) lung in­fec­tion [more in­for­ma­tion]
Vericel Corporation [VCEL] US$720 MM MCap
Ad­vanced cell ther­a­py; mar­ket­ing MA­CI (car­ti­lage re­pair) and Epi­cel (skin re­place­mentt) in TAMs of $2b+. Re­cent­ly ac­quired US com­mer­cial rights for Nexo­Brid. [more in­for­ma­tion]
Vivoryon [PRBGF] US$59 MM MCap
Vivo­ry­on's pro­grams are based on ded­i­cat­ed re­search, top-lev­el dis­cov­ery and de­ter­mined de­vel­op­ment. The com­pany de­vel­ops first-in-class medicines that tar­get post-trans­la­tio­n­al mod­i­fy­ing en­zymes. The pipe­line con­tains sev­er­al prod­uct can­di­dates across vari­ous stages of de­vel­op­ment, fo­cused on Alzheimer’s Dis­ease and on­col­o­gy. [more in­for­ma­tion]
ZAI Laboratory [ZLAB] US$2,233 MM MCap
The Com­pany has a broad pipe­line of 4 late-stage as­sets with rights in greater Chi­na and 3 as­sets with glob­al rights. Lead Can­di­date, Ni­ra­parib, is in Ph 3 de­vel­op­ment for Ovarian can­cer and is ex­pect­ed to be the first lo­cal PARP in­hibi­tor in Chi­na with­out a bio­mark­er test. [more in­for­ma­tion]